Search research articles
Contact Us
Filters
Showing results (131-140 of 231) with videos related to
Page
of 24
Sort By:
American Journal of Hematology
|
November 27, 2018
Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma
Nicholas Mackrides, Jennifer Chapman, Melissa C Larson, et al.
American Journal of Hematology
|
September 20, 2018
The association of physical activity before and after lymphoma diagnosis with survival outcomes
Priyanka A Pophali, Andrew Ip, Melissa C Larson, et al.
Haematologica
|
November 25, 2017
Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
Sean I Tracy, Thomas M Habermann, Andrew L Feldman, et al.
Leukemia & Lymphoma
|
April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma
Kristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Blood Cancer Journal
|
August 3, 2018
History of autoimmune conditions and lymphoma prognosis
Geffen Kleinstern, Matthew J Maurer, Mark Liebow, et al.
Hematological Oncology
|
June 11, 2016
FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts
Hervé Ghesquières, Beth R Larrabee, Corinne Haioun, et al.
British Journal of Haematology
|
March 10, 2026
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes
George A Cholack, Raphael Mwangi, Prokop Vodička, et al.
British Journal of Haematology
|
May 30, 2018
Human Pegivirus infection and lymphoma risk and prognosis: a North American study
Angelo Fama, Jinhua Xiang, Brian K Link, et al.
American Journal of Hematology
|
April 12, 2014
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells
Clive S Zent, Ronald P Taylor, Margaret A Lindorfer, et al.
American Journal of Hematology
|
March 18, 2014
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma
Heather L Gustafson, Song Yao, Bryan H Goldman, et al.
Page
of 24
Search research articles
Search
Showing results (131-140 of 231) with videos related to
Sort By:
Page
of 24
American Journal of Hematology
|
November 27, 2018
Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma
Nicholas Mackrides, Jennifer Chapman, Melissa C Larson, et al.
American Journal of Hematology
|
September 20, 2018
The association of physical activity before and after lymphoma diagnosis with survival outcomes
Priyanka A Pophali, Andrew Ip, Melissa C Larson, et al.
Haematologica
|
November 25, 2017
Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
Sean I Tracy, Thomas M Habermann, Andrew L Feldman, et al.
Leukemia & Lymphoma
|
April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma
Kristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Blood Cancer Journal
|
August 3, 2018
History of autoimmune conditions and lymphoma prognosis
Geffen Kleinstern, Matthew J Maurer, Mark Liebow, et al.
Hematological Oncology
|
June 11, 2016
FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts
Hervé Ghesquières, Beth R Larrabee, Corinne Haioun, et al.
British Journal of Haematology
|
March 10, 2026
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes
George A Cholack, Raphael Mwangi, Prokop Vodička, et al.
British Journal of Haematology
|
May 30, 2018
Human Pegivirus infection and lymphoma risk and prognosis: a North American study
Angelo Fama, Jinhua Xiang, Brian K Link, et al.
American Journal of Hematology
|
April 12, 2014
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells
Clive S Zent, Ronald P Taylor, Margaret A Lindorfer, et al.
American Journal of Hematology
|
March 18, 2014
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma
Heather L Gustafson, Song Yao, Bryan H Goldman, et al.
Page
of 24